You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

LEUPROLIDE ACETATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for leuprolide acetate and what is the scope of freedom to operate?

Leuprolide acetate is the generic ingredient in nine branded drugs marketed by Invagen Pharms, Ortho Mcneil Janssen, Abbvie Endocrine Inc, Tolmar, Amneal, Eugia Pharma, Genzyme, Meitheal, Rk Pharma, Sandoz, Sun Pharm, UBI, and Abbvie Endocrine, and is included in twenty-two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Leuprolide acetate has forty-six patent family members in twenty-eight countries.

There are sixteen drug master file entries for leuprolide acetate. Eleven suppliers are listed for this compound.

Drug Prices for LEUPROLIDE ACETATE

See drug prices for LEUPROLIDE ACETATE

Recent Clinical Trials for LEUPROLIDE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NRG OncologyPhase 2
Johns Hopkins Bloomberg School of Public HealthPhase 2
TakedaPhase 4

See all LEUPROLIDE ACETATE clinical trials

Pharmacology for LEUPROLIDE ACETATE
Medical Subject Heading (MeSH) Categories for LEUPROLIDE ACETATE

US Patents and Regulatory Information for LEUPROLIDE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-007 Aug 15, 2011 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-005 Jan 21, 1994 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020011-002 Oct 26, 1995 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LEUPROLIDE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-008 Aug 15, 2011 ⤷  Subscribe ⤷  Subscribe
Abbvie Endocrine Inc LUPRON DEPOT-PED KIT leuprolide acetate POWDER;INTRAMUSCULAR 020263-006 Jan 21, 1994 ⤷  Subscribe ⤷  Subscribe
Tolmar ELIGARD KIT leuprolide acetate POWDER;SUBCUTANEOUS 021731-001 Dec 14, 2004 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LEUPROLIDE ACETATE

Country Patent Number Title Estimated Expiration
China 116847900 用于混合注射器阀门组件的系统和方法 (Systems and methods for hybrid syringe valve assembly) ⤷  Subscribe
Georgia, Republic of P20125597 SUSTAINED-RELEASE COMPOSITION AND PRODUCTION METHOD THEREOF ⤷  Subscribe
Brazil PI0720582 COMPOSIÇÃO DE LIBERAÇÃO PROLONGADA, PROCESSO PARA A PREPARAÇÃO DA MESMA, COMPOSIÇÃO FARMACÊUTICA, AGENTE PROFILÁTICO OU TERAPÊUTICO PARA O CÂNCER DA PRÓSTATA, AGENTE PROFILÁTICO PARA A RECORRÊNCIA PÓS-OPERATÓRIA DE CÃNCER DE MAMA PRÉ-MENOPAUSA, E, USO DA COMPOSIÇÃO DE LIBERAÇÃO PROLONGADA ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

LEUPROLIDE ACETATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Leuprolide Acetate

Introduction to Leuprolide Acetate

Leuprolide acetate is a synthetic nonapeptide analog of the naturally occurring gonadotropin-releasing hormone (GnRH). It is widely used in the treatment of various conditions, including advanced prostate cancer, endometriosis, and precocious puberty. The market for leuprolide acetate is experiencing significant growth, driven by several key factors.

Market Size and Valuation

As of 2022, the leuprolide acetate market was valued at over USD 2 billion. This valuation is expected to grow substantially, with projections indicating a Compound Annual Growth Rate (CAGR) of around 6% between 2023 and 2032, reaching approximately USD 3.5 billion by 2032[1][4].

Growth Drivers

Increasing Incidence of Cancer

The rising global incidence of cancer, particularly prostate cancer, is a major driver of the leuprolide acetate market. Prostate cancer is the second-most common type of cancer among men, especially those over 50 years old. Leuprolide acetate is prescribed to lower testosterone levels, which helps slow down the growth of cancer cells. This hormonal therapy is often used in combination with radiation therapy, further boosting its demand[3][4].

Endometriosis and Other Conditions

In addition to cancer, the growing female population suffering from endometriosis is another significant factor. Endometriosis affects approximately 176 million women worldwide and 11% of American women between the ages of 15 to 44. Leuprolide acetate aids in complete preoperative pain relief for these patients, contributing to the market's growth[1].

Regulatory Approvals and R&D

Favorable regulatory landscapes, particularly in regions like North America, are supporting market growth. For instance, the U.S. FDA has approved several leuprolide acetate products, such as the leuprolide acetate injection kit by Eugia Pharma Specialty Limited in June 2022. Companies like Cipla Limited are also introducing new FDA-approved products, expanding their product portfolios and customer bases[1].

Distribution Channels

The leuprolide acetate market is segmented by distribution channels, including retail pharmacy, hospital pharmacy, and online pharmacy. The online pharmacy segment is expected to grow significantly, with a CAGR of more than 6% over the forecast period. This growth is attributed to the increasing patient inclination towards online shopping, especially post-COVID-19, and the wide reachability and inclusion of cutting-edge products on e-commerce platforms[1].

Regional Market Dynamics

North America

North America holds the largest share of the leuprolide acetate market, accounting for over 39% of the industry share in 2022. The region's growth is driven by rising cancer incidences and a favorable regulatory environment. Increased healthcare spending in the U.S., which rose by over 2% in 2021, also contributes to higher demand for leuprolide acetate[1][4].

Europe

Europe is the second-largest market for leuprolide acetate, driven by advancements in medical care and the development of more effective treatments for conditions like prostate cancer and fertility issues. The region's healthcare infrastructure and increasing adoption of leuprolide acetate are key factors in its market growth[4].

Challenges and Pitfalls

Drug Price Control Policies

Strict drug price-control policies are a significant challenge for the leuprolide acetate market. These policies can lower prescription prices but also reduce Research and Development (R&D) funding, impacting business growth. For example, drug price control schemes in the U.S. can lower prescription prices by 40 to 50%, resulting in a 30 to 60% reduction in R&D funding[1].

COVID-19 Impact

The COVID-19 pandemic had a mixed impact on the leuprolide acetate market. While it disrupted supply chains and R&D processes, it also increased the adoption of online pharmacies and remote healthcare services, which benefited the market in some aspects[1].

Product Forms and Administration

Leuprolide acetate is available in various forms, including depot suspensions for 1-month, 3-month, 4-month, and 6-month administrations. These products, such as LUPRON DEPOT, must be administered in a doctor’s office and are not suitable for patients with allergic reactions to similar drugs. The initial therapy can cause a temporary increase in testosterone levels and worsening symptoms of prostate cancer[2].

Financial Support and Savings Programs

To make leuprolide acetate more accessible, various savings and support programs are available. For example, the LUPRON DEPOT Savings Card can help eligible patients pay as little as $10 per month or $600 per quarter, depending on the treatment frequency and insurance plan[5].

Key Players and Strategic Moves

Major pharmaceutical companies, such as Cipla Limited and Aurobindo Pharma Ltd., are actively involved in the leuprolide acetate market. These companies are engaging in rigorous R&D programs and strategic collaborations to expand their product portfolios and customer bases. Such initiatives are expected to enhance the business scenario and drive market growth[1].

Future Outlook

The leuprolide acetate market is poised for significant growth, driven by the increasing incidence of cancer, advancements in medical care, and favorable regulatory environments. Despite challenges such as drug price control policies, the market is expected to reach USD 5.41 billion by 2037, with a CAGR of around 6.8% during the forecast period[4].

Key Takeaways

  • The leuprolide acetate market was valued at over USD 2 billion in 2022 and is expected to grow at a CAGR of around 6% until 2032.
  • Rising cancer incidences, particularly prostate cancer, and the growing prevalence of endometriosis are key drivers of market growth.
  • North America and Europe are the largest markets, driven by favorable regulatory environments and advancements in medical care.
  • Online pharmacies are expected to grow significantly due to increased patient inclination towards online shopping.
  • Drug price control policies and the COVID-19 pandemic present challenges but also offer opportunities for market adaptation.

FAQs

What is leuprolide acetate used for?

Leuprolide acetate is used in the treatment of advanced prostate cancer, endometriosis, and precocious puberty. It works by lowering testosterone levels, which helps slow down the growth of cancer cells and alleviates symptoms of other conditions.

How is leuprolide acetate administered?

Leuprolide acetate is administered via depot suspension injections, available for 1-month, 3-month, 4-month, and 6-month durations. These injections must be given in a doctor’s office.

What are the potential side effects of leuprolide acetate?

Initial therapy with leuprolide acetate can cause a temporary increase in testosterone levels, leading to worsening symptoms of prostate cancer, such as urinary symptoms and bone pain. Patients may also experience allergic reactions.

How does the COVID-19 pandemic impact the leuprolide acetate market?

The COVID-19 pandemic disrupted supply chains and R&D processes but also increased the adoption of online pharmacies and remote healthcare services, which benefited the market in some aspects.

What savings programs are available for leuprolide acetate?

Savings programs like the LUPRON DEPOT Savings Card can help eligible patients pay as little as $10 per month or $600 per quarter, depending on the treatment frequency and insurance plan.

Sources

  1. GMI Insights: Leuprolide Acetate Market Share | Forecasts Report, 2023-2032.
  2. Lupron Prostate Cancer: LUPRON DEPOT for advanced prostate cancer.
  3. BioSpace: Global Leuprolide Acetate Market Opportunities and Growth Analysis Report.
  4. Research Nester: Leuprolide Acetate Market Size & Share | Forecast Report 2037.
  5. Lupron Gyn: LUPRON DEPOT® Copay Savings Card.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.